Get the Weekly Intelligence Brief — top committee picks every Sunday.
MCK · NYSE · STOCK

McKesson (MCK) Stock Analysis

Healthcare Updated October 10, 2026
$938.60
52W $723.68 – $999.00
57/100
$109.92B
25.0
0.30
AI Committee Verdict
Watch
57/100
Conviction: Moderate · 67% agreement · 6 analysts
+6.4%
-15.8%
0.40:1
Moderate

Is MCK Bullish or Bearish?

Mixed. Innellis AI committee rates McKesson Corporation (MCK) Watch with a composite score of 57/100 , based on 6 analysts with 67% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +3.29 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -16.71 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Supporting evidence favours the bullish case. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • ROE of 39.4% shows genuine earnings power backing the valuation — Value
  • EPS growing 49.1% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • Price-to-book of 4.3x prices in significant intangible value — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • RSI at 71 is in overbought territory — Technical
  • Current ratio of 0.85 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
57/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 53%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 39.4% shows genuine earnings power backing the valuation
− Price-to-book of 4.3x prices in significant intangible value
Growth Analyst bullish
60 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 49.1% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 71 is in overbought territory
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.85 is tight -- limited short-term liquidity cushion
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 66 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.3 to 56.7.

Analyst-level changes:
  • News Analyst: +1 bullish signal(s).
  • Technical Analyst: score 69->61 (-8); +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
71.4
Overbought
MACD Histogram
5.867
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$789.96
Resistance
$998.34
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$911.40 Above
EMA 21
$897.76 Above
EMA 50
$879.89 Above
EMA 200
$839.91 Above

Fundamental Analysis

Valuation
87
Growth
65
Profitability
16
Financial Health
54
Cash Flow
70
Valuation
P/E Ratio 25.0×
P/B Ratio -26.28×
PEG Ratio 0.51
Dividend Yield 0.36%
52W High $999.00
52W Low $723.68
Quality & Growth
ROE -21924.5%
ROA 578.5%
Gross Margin 363.9%
Operating Margin 161.9%
Revenue Growth YoY —
Debt / Equity -2.76
AI Fundamental Assessment
P/E ratio of 25.0 (moderate relative to a 15-40x range); Price-to-book of -26.3x; PEG ratio of 0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -219.2%; Return on assets of 5.8%; Net margin of 1.1%; Gross margin of 3.6%; Current ratio of 0.89 (tight short-term liquidity); Debt-to-equity of -2.76; Free cash flow per share is positive (52.11); Most recent quarter beat estimates by 3.1%; 5 consecutive earnings beats; EPS growth decelerating (+25.2% -> -15.1% QoQ); Average YoY EPS growth of 20.2%; Analyst estimates rising over recent quarters
Get the Full MCK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime